Literature DB >> 11454916

Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system.

Y T Shen1, T J Pittman, P S Buie, D L Bolduc, S A Kane, K S Koblan, R J Gould, J J Lynch.   

Abstract

It remains unknown whether the extent of vasoactive response to exogenous calcitonin gene-related peptide (CGRP) varies among different regional vascular beds. It is also unclear whether endogenous CGRP plays a functional role in regulating basal vascular activity. To address these two issues, experiments were conducted in 27 anesthetized rats instrumented with a carotid flow probe and catheters in a jugular vein, left ventricle (LV), and femoral artery, and in 6 conscious dogs, chronically instrumented with LV pressure gauge, aortic and atrial catheters, and ascending aortic, coronary, carotid, and renal flow probes. In both species, administration of human alpha-CGRP (0.1-0.5 microg/kg, i.v.) induced a dose-dependent peripheral vasodilation that was completely abolished by pretreatment with alpha-CGRP[8-37] (30 microg/kg/min, i.v.), a competitive antagonist of CGRP receptors. Regional blood flow measured by the radioactive microsphere technique in rats showed that the alpha-CGRP (0.3 microg/kg, i.v.)-induced increase in blood flow was greater (p < 0.05) in the heart (+53 +/- 16%) than in the brain (+14 +/- 6%). In the presence of beta-adrenergic receptor blockade with propranolol, however, the increases in blood flow in these two vascular beds were identical. In conscious dogs, alpha-CGRP (0.3 microg/kg, i.v.) produced similar increases in coronary (+24 +/- 6%), carotid (+26 +/- 3%), and renal (+26 +/- 6%) blood flow, which were different from the patterns induced by other vasodilators; at an equivalent level of reduction in mean arterial pressure and total peripheral resistance, alpha-CGRP increased coronary and carotid blood flow significantly less (p < 0.05) than adenosine or nitroprusside. Unlike alpha-CGRP, adenosine and nitroprusside, as expected, induced pronounced differential blood flow changes in these vascular beds. Neither systemic hemodynamics nor regional blood flow distribution was altered by the administration of a pharmacological blocking dose of alpha-CGRP[8-37] in the two species. Thus, we conclude that endogenous alpha-CGRP does not play an important role in cardiovascular regulation under normal, resting conditions, although exogenous alpha-CGRP induces a marked, comparable vasorelaxation in different regional vascular beds.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454916

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Activation of intestinal spinal afferent endings by changes in intra-mesenteric arterial pressure.

Authors:  A Humenick; B N Chen; L Wiklendt; N J Spencer; V P Zagorodnyuk; P G Dinning; M Costa; S J H Brookes
Journal:  J Physiol       Date:  2015-06-25       Impact factor: 5.182

2.  Calcitonin gene-related peptide antagonism attenuates the haemodynamic and glycaemic responses to acute hypoxaemia in the late gestation sheep fetus.

Authors:  A S Thakor; M R Bloomfield; M Patterson; D A Giussani
Journal:  J Physiol       Date:  2005-04-28       Impact factor: 5.182

3.  Neuropeptide release augments serum albumin loss and reduces ultrafiltration in peritoneal dialysis.

Authors:  Nicola Cavallini; Dick Delbro; Gunnar Tobin; Magnus Braide
Journal:  Perit Dial Int       Date:  2011-09-30       Impact factor: 1.756

4.  Role of the transient receptor potential vanilloid type 1 receptor and stretch-activated ion channels in nitric oxide release from endothelial cells of the aorta and heart in rats.

Authors:  Juan Carlos Torres-Narváez; Leonardo Del Valle Mondragón; Elvira Varela López; Israel Pérez-Torres; Julieta Anabell Díaz Juárez; Jorge Suárez; Gustavo Pastelín Hernández
Journal:  Exp Clin Cardiol       Date:  2012-09

5.  Cardiovascular action of insulin-like growth factor-1 is not mediated by calcitonin gene-related peptide neurons.

Authors:  Crystal R McRae; Sumangala P Rao; Joseph C Dunbar
Journal:  Endocrine       Date:  2002-11       Impact factor: 3.633

6.  Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs.

Authors:  Kapil Kapoor; Udayasankar Arulmani; Jan P C Heiligers; Ingrid M Garrelds; Edwin W Willems; Henri Doods; Carlos M Villalón; Pramod R Saxena
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

Authors:  Simon R Sinclair; Stefanie A Kane; Bart J Van der Schueren; Alan Xiao; Kenneth J Willson; Janet Boyle; Inge de Lepeleire; Yang Xu; Lisa Hickey; William S Denney; Chi-Chung Li; John Palcza; Floris H M Vanmolkot; Marleen Depré; Anne Van Hecken; M Gail Murphy; Tony W Ho; Jay N de Hoon
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

8.  The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS blocks CGRP and adrenomedullin vasoactive responses in the microvasculature.

Authors:  A D Grant; C W Tam; Z Lazar; M K Shih; S D Brain
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

9.  CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat.

Authors:  J Zeller; K T Poulsen; J E Sutton; Y N Abdiche; S Collier; R Chopra; C A Garcia; J Pons; A Rosenthal; D L Shelton
Journal:  Br J Pharmacol       Date:  2008-09-08       Impact factor: 8.739

10.  Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation.

Authors:  S Akerman; H Kaube; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.